EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinieOpen Access · CC BY 4.0

Prostate Cancer Working Group 4 Recap

Aravind S Ravi Kumar, Aaron R Hansen

European Urology Focus · 2026-10 · 12 (5) · 880-882

DOI: 10.1016/j.euf.2026.06.007 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Urology Focus, 2026-10. Verfasst von Aravind S Ravi Kumar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Theranostics Centre, Department of Radiology, Princess Alexandra Hospital, Brisbane, Australia; School of Medicine, University of Queensla…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Clinical Trials as Topic. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Prostate Cancer Clinical Trials Working Group (PCWG) recommendations have guided the design and interpretation of prostate cancer trials for more than two decades. Rapid advances in molecular diagnostics, imaging, and systemic therapies have substantially altered the clinical landscape, prompting the recent update to the framework. PCWG4 introduces a shift towards patient-centred terminology and end points, incorporating molecular and imaging biomarkers for trial eligibility and response assessment. The updated guidance also provides recommendations for integrating Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography into clinical trial frameworks and proposes revised definitions of radiographic progression. PCWG4 emphasises the use of patient-reported outcome measures and introduces the concept of "no longer clinically benefitting" to guide treatment continuation beyond conventional progression end points. This recap summarises key updates in PCWG4 and highlights their implications for contemporary prostate cancer clinical trial design and interpretation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsClinical Trials as TopicHumansMaleBiomarkers, TumorProstate-Specific AntigenPositron Emission Tomography Computed TomographyDisease ProgressionPatient Reported Outcome Measures

Stichwörter der Autor:innen

Clinical trialsPCWG4PSMAProstate cancer

Substanzen

Biomarkers, TumorProstate-Specific Antigen

Autor:innen und Institutionen

  • Integrated Theranostics Centre, Department of Radiology, Princess Alexandra Hospital, Brisbane, Australia; School of Medicine, University of Queensland, Queensland, Australia. Electronic address: aravind.ravikumar@healt…
  • School of Medicine, University of Queensland, Queensland, Australia; Integrated Theranostics Centre, Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Australia.

Zitieren

APA

Ravi Kumar, A. S., & Hansen, A. R. (2026). Prostate Cancer Working Group 4 Recap. European Urology Focus, 12(5), 880-882. https://doi.org/10.1016/j.euf.2026.06.007

Vancouver

Ravi Kumar AS, Hansen AR. Prostate Cancer Working Group 4 Recap. European Urology Focus. 2026;12(5):880-882. doi:10.1016/j.euf.2026.06.007

BibTeX
@article{RaviKumar2026,
  author = {Ravi Kumar, Aravind S and Hansen, Aaron R},
  title = {Prostate Cancer Working Group 4 Recap},
  journal = {European Urology Focus},
  year = {2026},
  volume = {12},
  number = {5},
  pages = {880--882},
  doi = {10.1016/j.euf.2026.06.007}
}
Kostenlos starten →